SCHEMBL17216748

SCHEMBL17216748

CCc1cccc([C]=NOCc2ccc(-c3ccccc3)cc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 1/20 0.40
▸ AGXT P21549 3/20 0.38
▸ IDO1 P14902 2/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ PTGS2 P35354 1/20 0.37
▸ GSTP1 P09211 1/20 0.37
▸ NAAA Q02083 4/20 0.35
▸ TP53 P04637 1/20 0.34
▸ TAAR1 Q96RJ0 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ FGFR1 P11362 1/20 0.33
▸ S1PR1 P21453 1/20 0.33
▸ MME P08473 1/20 0.33
▸ ENPP2 Q13822 1/20 0.33
▸ GABRG2 P18507 1/20 0.33
▸ GABRB3 P28472 1/20 0.33
▸ GABRA5 P31644 1/20 0.33
▸ GABRA3 P34903 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17216746 1.00 BCL2 (0.40) BCL2AGXTIDO1NPC1RAB9A
SCHEMBL17216570 0.93 TP53 (0.39) NPC1RAB9ATP53SMN1; SMN2L3MBTL1
SCHEMBL17216567 0.93 TP53 (0.39) NPC1RAB9ATP53SMN1; SMN2L3MBTL1
SCHEMBL17218182 0.92 AGXT (0.45) BCL2AGXTPTGS2NAAAFGFR1
SCHEMBL17218178 0.92 AGXT (0.45) BCL2AGXTPTGS2NAAAFGFR1
SCHEMBL17215896 0.90 TP53 (0.35) NPC1RAB9ATP53SMN1; SMN2L3MBTL1
SCHEMBL17215895 0.90 TP53 (0.35) NPC1RAB9ATP53SMN1; SMN2L3MBTL1
SCHEMBL17218868 0.86 MAOB (0.37) AGXTIDO1NPC1RAB9ASMN1; SMN2
SCHEMBL17218871 0.86 MAOB (0.37) AGXTIDO1NPC1RAB9ASMN1; SMN2
SCHEMBL17215731 0.86 IDO1 (0.42) AGXTIDO1NPC1RAB9AGSTP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 BCL2 1159/4885AGXT 1423/4885IDO1 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback